RNS Number : 7957X
Deltex Medical Group PLC
30 June 2008
Deltex Medical Group plc
Early results presented from major trial using CardioQ-ODM* in urological surgery
30 June 2008 - Deltex Medical Group plc ("Deltex Medical" or "the Company"), the UK's leading haemodynamic
monitoring company, today
announces the first presentation of early results from a significant new clinical trial using the CardioQ-ODM in major
bladder surgery.
In a presentation to the annual meeting of the British Association of Urological Surgeons in Manchester, doctors
from the Freeman
Hospital in Newcastle-upon-Tyne set out the results of the pilot phase of their blinded prospective randomised
controlled trial on
ODM-guided fluid management during major urological surgery. The results cover the first 40 patients enrolled into the
study and are
therefore not yet statistically significant. However, they indicate results consistent with previous trials in other
types of surgery
including reduced post-operative complications and reduced lengths of hospital stay.
The full study is designed to include over 100 patients and the doctors expect it to take at least another 18
months to complete,
although further interim results may become available sooner.
Andy Hill, Deltex Medical's Chief Executive commented:
"We are excited that the promising results of the pilot phase of this trial are already being presented to a major
meeting of specialist
urological surgeons and have started to plan for specifically targeting this group over the medium term as more results
come through.
The Freeman Hospital's earlier trial into using CardioQ-ODM in bowel surgery has had a positive impact in all our
target markets with a
growing number of hospitals in the UK and Europe protocolising the use of the CardioQ-ODM in their standard operating
procedures. In the
event that the full study bears out the preliminary results of the pilot phase we would expect this trial to have a
similar positive
impact."
For further information, please contact:
Deltex Medical Group plc 01243 774 837
Nigel Keen, Chairman njk@deltexmedical.com
Andy Hill, Chief Executive ahill@deltexmedical.com
Ewan Phillips, Finance Director eap@deltexmedical.com
Gavin Anderson & Company 020 7554 1400
Deborah Walter dwalter@gavinanderson.co.uk
Robert Speed rspeed@gavinanderson.co.uk
Charles Stanley Securities 020 7149 6000
(Nominated Adviser)
Philip Davies philip.davies@csysecurities.com
Russell Cook russell.cook@csysecurities.com
Notes for Editors
Deltex Medical manufactures and markets the CardioQ-ODM* monitor, which uses disposable ultra-sound probes inserted
into the oesophagus
to determine the amount of blood being pumped around the body - 'circulating blood volume'. Reduced circulating blood
volume is known as
hypovolaemia, which leads to insufficient oxygen being delivered to the organs. This causes medical complications
including peripheral and
major organ failure which can lead to death. Hypovolaemia, which is akin to severe dehydration, affects virtually every
patient having
surgery because of the combined effects of pre-operative starvation, the impact of the anaesthetic agents and trauma
from the surgery
itself. Using fluids and drugs, guided by the CardioQ-ODM, to optimise the amount of circulating blood significantly
reduces post-operative
complications allowing patients to make a faster, more complete recovery and return home earlier.
The CardioQ-ODM incorporates the Company's proprietary software and a small diameter, easy-to-use, minimally
invasive, disposable
oesophageal probe that is used for transmitting and receiving an ultra-sound signal. By using this technology, the
CardioQ-ODM provides
clinicians with the ability to haemodynamically optimise critically ill patients and those undergoing routine moderate
to major surgery
through the controlled administration of fluid and drugs. Haemodynamic optimisation has been scientifically proven to
improve the speed and
quality of patient recovery and reduce hospital stay.
There are already over 1,500 CardioQ-ODMs currently in use in hospitals worldwide and distribution arrangements are in
place in over 30
countries. In addition, there are currently more than 100 clinical publications on the use of the CardioQ-ODM which
have repeatedly:-
* Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the
technology works
* Proved that the CardioQ-ODM works in a wide range of surgical procedures
* Demonstrated that the Company's technology provides significant health and economic benefits by helping to
reduce post-operative
complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients.
The SupraQ* is an entirely non-invasive device which uses an ultrasound probe held at the base of the patient's
neck to track the flow
of blood in the aorta; it presents the same data as the CardioQ-ODM in a similar format and is used for taking
snapshots or monitoring over
short periods.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAKKXALSPEFE
|